KADCYLA is the first HER2-targeted antibody-drug conjugate

Explore KADCYLA’s components and molecular structure and proposed mechanism of action.

Explore the molecular structure

KADCYLA is a single drug with 3 components.


Proposed mechanism of action

KADCYLA delivers multiple HER2-targeted antitumor activities.

Request more information

Genentech Clinical Oncology Specialists are available to answer your questions about KADCYLA.